OBJECTIVE: Attrition from treatment in the short and long term for major depressive disorder (MDD) is clearly an adverse outcome. To assist in tailoring the delivery of interventions to specific patients to reduce attrition, this study reports the incidence, timing, and predictors of attrition from outpatient treatment in public mental health clinics. METHODS: Outpatients with psychotic and nonpsychotic MDD receiving measurement-based care in the Texas Medication Algorithm Project (N=179) were evaluated to determine timing and rates of attrition as well as baseline sociodemographic, clinical, and attitudinal predictors of attrition. RESULTS: Overall, 23% (42/179) of the patients left treatment by 6 months, and 47% (84/179) left by 12 months. Specific beliefs about the impact of medication, such as its perceived harmfulness, predicted attrition at both 6 and 12 months. Younger age (P=0.0004) and fewer side effects at baseline (P=0.0376) were associated with attrition at 6 months. Younger age (P=0.0013), better perceived physical functioning (P=0.0007), and more negative attitudes about psychiatric medications at baseline (P=0.0075) were associated with attrition at 12 months. CONCLUSIONS: Efforts to elicit attitudes about medications and tailoring educational and other retention interventions for patients with negative beliefs about antidepressants both when initiating a new medication and throughout treatment may reduce attrition. Particular focus on younger patients and those requiring frequent visits may be helpful.
OBJECTIVE: Attrition from treatment in the short and long term for major depressive disorder (MDD) is clearly an adverse outcome. To assist in tailoring the delivery of interventions to specific patients to reduce attrition, this study reports the incidence, timing, and predictors of attrition from outpatient treatment in public mental health clinics. METHODS: Outpatients with psychotic and nonpsychotic MDD receiving measurement-based care in the Texas Medication Algorithm Project (N=179) were evaluated to determine timing and rates of attrition as well as baseline sociodemographic, clinical, and attitudinal predictors of attrition. RESULTS: Overall, 23% (42/179) of the patients left treatment by 6 months, and 47% (84/179) left by 12 months. Specific beliefs about the impact of medication, such as its perceived harmfulness, predicted attrition at both 6 and 12 months. Younger age (P=0.0004) and fewer side effects at baseline (P=0.0376) were associated with attrition at 6 months. Younger age (P=0.0013), better perceived physical functioning (P=0.0007), and more negative attitudes about psychiatric medications at baseline (P=0.0075) were associated with attrition at 12 months. CONCLUSIONS: Efforts to elicit attitudes about medications and tailoring educational and other retention interventions for patients with negative beliefs about antidepressants both when initiating a new medication and throughout treatment may reduce attrition. Particular focus on younger patients and those requiring frequent visits may be helpful.
Authors: M G Toprac; A J Rush; T M Conner; M L Crismon; M Dees; C Hopkins; V Rowe; S P Shon Journal: J Clin Psychiatry Date: 2000-07 Impact factor: 4.384
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Madhukar H Trivedi; A John Rush; Bradley N Gaynes; Jonathan W Stewart; Stephen R Wisniewski; Diane Warden; Louise Ritz; James F Luther; Diane Stegman; Joanne Deveaugh-Geiss; Robert Howland Journal: Neuropsychopharmacology Date: 2007-04-04 Impact factor: 7.853
Authors: Allison J Applebaum; Wendy G Lichtenthal; Hayley A Pessin; Julia N Radomski; N Simay Gökbayrak; Aviva M Katz; Barry Rosenfeld; William Breitbart Journal: Psychooncology Date: 2011-07-12 Impact factor: 3.894
Authors: Daniel Fernández; Daniel Vigo; Nancy A Sampson; Irving Hwang; Sergio Aguilar-Gaxiola; Ali O Al-Hamzawi; Jordi Alonso; Laura Helena Andrade; Evelyn J Bromet; Giovanni de Girolamo; Peter de Jonge; Silvia Florescu; Oye Gureje; Hristo Hinkov; Chiyi Hu; Elie G Karam; Georges Karam; Norito Kawakami; Andrzej Kiejna; Viviane Kovess-Masfety; Maria E Medina-Mora; Fernando Navarro-Mateu; Akin Ojagbemi; Siobhan O'Neill; Marina Piazza; Jose Posada-Villa; Charlene Rapsey; David R Williams; Miguel Xavier; Yuval Ziv; Ronald C Kessler; Josep M Haro Journal: Psychol Med Date: 2020-04-28 Impact factor: 7.723
Authors: Sudha Prathikanti; Renee Rivera; Ashly Cochran; Jose Gabriel Tungol; Nima Fayazmanesh; Eva Weinmann Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240
Authors: Jennifer Nicholas; Kit Huckvale; Mark Erik Larsen; Ashna Basu; Philip J Batterham; Frances Shaw; Shahbaz Sendi Journal: J Med Internet Res Date: 2017-02-28 Impact factor: 5.428